GGHC
TVRD

Gilder Gagnon Howe & Co’s Tvardi Therapeutics TVRD Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-776
Closed -$399K – 267
2015
Q3 		$399K Buy
+776
New +$519K 0.01% 214
2014
Q3 		– Sell
-257
Closed -$158K – 312
2014
Q2 		$158K Sell
257
-507
-66% -$273K ﹤0.01% 267
2014
Q1 		$512K Buy
+764
New +$452K 0.01% 228

Other funds holding TVRD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return

Gilder Gagnon Howe & Co's TVRD Position: Q4 2015 in Review

Gilder Gagnon Howe & Co sold out of Tvardi Therapeutics (TVRD) in Q4 2015, closing a stake of 776 shares — an estimated $399K sold.

Gilder Gagnon Howe & Co first reported a position in TVRD in Q1 2014 and held it in 3 quarters. The position peaked at $512K in Q1 2014. 95 funds tracked by Wall St. Rank hold TVRD as of Q4 2015.

  • Gilder Gagnon Howe & Co reported no remaining Tvardi Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 776 Tvardi Therapeutics shares in Q4 2015, an estimated $399K.
  • Gilder Gagnon Howe & Co first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 3 quarters.
  • Gilder Gagnon Howe & Co's Tvardi Therapeutics position peaked at $512K in Q1 2014.
  • 95 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2015, filed 4 Feb 2016.